CLIA Kit for Platelet Factor 4 (PF4)
CXCL4; SCYB4; Chemokine C-X-C-Motif Ligand 4; Oncostatin-A; Iroplact
- Product No.SCA172Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, platelet-poor plasma and cell culture supernates
- Test MethodDouble-antibody Sandwich
- Assay Length2h, 40min
- Detection Range0.41-300pg/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.17pg/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
For more details, please contact local distributors! 840 US$ 840
For more details, please contact local distributors! US$ 3780
For more details, please contact local distributors! US$ 7140
For more details, please contact local distributors! US$ 58800
For more details, please contact local distributors!
This assay has high sensitivity and excellent specificity for detection of Platelet Factor 4 (PF4).
No significant cross-reactivity or interference between Platelet Factor 4 (PF4) and analogues was observed.
Matrices listed below were spiked with certain level of recombinant Platelet Factor 4 (PF4) and the recovery rates were calculated by comparing the measured value to the expected amount of Platelet Factor 4 (PF4) in samples.
|Matrix||Recovery range (%)||Average(%)|
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Platelet Factor 4 (PF4) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Platelet Factor 4 (PF4) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
|Pre-coated, ready to use 96-well strip plate||1||Plate sealer for 96 wells||4|
|Detection Reagent A||1×120µL||Assay Diluent A||1×12mL|
|Detection Reagent B||1×120µL||Assay Diluent B||1×12mL|
|Substrate A||1×10mL||Substrate B||1×2mL|
|Wash Buffer (30 × concentrate)||1×20mL||Instruction manual||1|
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of ELISA / CLIA
- CLIA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Fast blue Protein Stain solution
|Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics||Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats PubMed: 20601223|
|Basic Research in Cardiology||Secretome of apoptotic peripheral blood cells (APOSEC) attenuates microvascular obstruction in a porcine closed chest reperfused acute myocardial infarction model: role of platelet aggregation and vasodilation PubMed: 22899170|
|PLoS One||Platelets Recognize Brain-Specific Glycolipid Structures, Respond to Neurovascular Damage and Promote Neuroinflammation PubMed: PMC3608633|
|Diving and Hyperbaric Medicine||Effect of splenectomy on platelet activation and decompression sickness outcome in a rat model of decompression Pubmed:25311322|
|Journal of Functional Foods||A Phellinus baumii–based supplement containing Salvia miltiorrhiza Bunge improves atherothrombotic profiles through endothelial nitric oxide synthase and cyclooxygenase pathwaysin vitro and in vivo science:S1756464616300676|
|Plos one||Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury pubmed:27583400|
|international journal of molecular sciences||Evidence of the Role of R-Spondin 1 and Its Receptor Lgr4 in the Transmission of Mechanical Stimuli to Biological Signals for Bone Formation. pubmed:28272338|
|Experimental and Therapeutic Medicine||Feasibility of improving platelet‑rich plasma therapy by using chitosan with high platelet activation ability pubmed:28450960|
|Reproductive Toxicology||Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats Pubmed: 30528429|
|INTERNATIONAL JOURNAL OF CARDIOLOGY||Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation Pubmed: 30857843|
|Available at SSRN 3335365||Evaluating the Platelet Activation Related to the Degradation of Biomaterials by Scheme of Molecular Markers|
|journal of biotechnology||Newly Identified HNP‐F from Human Neutrophil Peptide 1 Promotes Hemostasis Pubmed: 30927490|
|Data in Brief||Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation|
|journal of thoracic and cardiovascular surgery||Evaluating Platelet Activation Related to the Degradation of Biomaterials Using Molecular Markers Pubmed: 32812629|
|Marine Drugs||The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents Pubmed: 31533230|
|Thrombosis Research||Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices Pubmed: 31838449|
|Nat Commun||The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets 34099640|
|Vaccine||The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats Pubmed:35183388|
|Catalog No.||Related products for research use of Homo sapiens (Human) Organism species||Applications (RESEARCH USE ONLY!)|
|APA172Hu01||Active Platelet Factor 4 (PF4)||Cell culture; Activity Assays.|
|RPA172Hu01||Recombinant Platelet Factor 4 (PF4)||Positive Control; Immunogen; SDS-PAGE; WB.|
|PAA172Hu01||Polyclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC; IP.|
|LAA172Hu71||Biotin-Linked Polyclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC.|
|LAA172Hu81||FITC-Linked Polyclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC; IF.|
|MAA172Hu21||Monoclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC; IP.|
|MAA172Hu23||Monoclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC; IP.|
|MAA172Hu22||Monoclonal Antibody to Platelet Factor 4 (PF4)||WB; IHC; ICC; IP.|
|SEA172Hu||ELISA Kit for Platelet Factor 4 (PF4)||Enzyme-linked immunosorbent assay for Antigen Detection.|
|SCA172Hu||CLIA Kit for Platelet Factor 4 (PF4)||Chemiluminescent immunoassay for Antigen Detection.|
|LMA172Hu||Magnetic Luminex Assay Kit for Platelet Factor 4 (PF4)||Magnetic Luminex Assay for Antigen Detection.|
|PSA172Hu01||Antibody Pair for Platelet Factor 4 (PF4)||ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.|
|KSA172Hu01||ELISA Kit DIY Materials for Platelet Factor 4 (PF4)||Main materials for "Do It (ELISA Kit) Yourself".|